Related Experiment Video
Updated: Jun 6, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Promise and challenge of RNA interference-based therapy for cancer
Fabio Petrocca1, Judy Lieberman
1200 Longwood Avenue, WAB 255, Boston, MA 02115, USA.
Abstract:
Cancer therapeutics still fall far short of our goals for treating patients with locally advanced or metastatic disease. Until recently, almost all cancer drugs were crude cytotoxic agents that discriminate poorly between cancer cells and normally dividing cells. The development of targeted biologics that recognize tumor cell surface antigens and of specific inhibitors of pathways dysregulated in cancer cells or normal cellular pathways on which a cancer cell differentially depends has provided hope for converting our increasing understanding of cellular transformation into intelligently designed anticancer therapeutics. However, new drug development is painfully slow, and the pipeline of new therapeutics is thin. The discovery of RNA interference (RNAi), a ubiquitous cellular pathway of gene regulation that is dysregulated in cancer cells, provides an exciting opportunity for relatively rapid and revolutionary approaches to cancer drug design. Small RNAs that harness the RNAi machinery may become the next new class of drugs for treating a variety of diseases. Although it has only been 9 years since RNAi was shown to work in mammalian cells, about a dozen phase I to III clinical studies have already been initiated, including four for cancer. So far there has been no unexpected toxicity and suggestions of benefit in one phase II study. However, the obstacles for RNAi-based cancer therapeutics are substantial. This article will discuss how the endogenous RNAi machinery might be harnessed for cancer therapeutics, why academic researchers and biotech and pharmaceutical companies are so excited, and what the obstacles are and how they might be overcome.
Insights
RNA interference (RNAi) offers a promising new avenue for cancer drug development, potentially leading to rapid therapeutic advancements. Harnessing this gene regulation pathway presents significant opportunities and challenges for treating advanced cancers.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Current cancer therapeutics, primarily cytotoxic agents, have limitations in treating advanced disease.
- Targeted biologics and pathway inhibitors represent advances but face slow development and a thin pipeline.
- The discovery of RNA interference (RNAi) provides a novel mechanism for gene regulation with therapeutic potential.
Purpose of the Study:
- To explore the potential of harnessing the endogenous RNA interference (RNAi) machinery for cancer therapeutics.
- To discuss the excitement surrounding RNAi-based cancer drug design in academic and industry settings.
- To identify and address the substantial obstacles hindering the development of RNAi cancer therapeutics.
Main Methods:
- Review of the RNA interference (RNAi) pathway and its dysregulation in cancer cells.
- Analysis of ongoing clinical studies involving RNAi-based therapeutics, including those for cancer.
- Discussion of the challenges and potential strategies for overcoming obstacles in RNAi drug development.
Main Results:
- RNA interference (RNAi) is a ubiquitous gene regulatory pathway implicated in cancer.
- Several clinical studies (Phase I-III) utilizing RNAi therapeutics have been initiated, with some showing early promise.
- No unexpected toxicities have been reported, and one Phase II study suggested potential benefits.
Conclusions:
- RNA interference (RNAi) machinery offers a revolutionary approach for developing novel cancer therapeutics.
- Despite substantial obstacles, the rapid progress and early clinical success suggest a bright future for RNAi-based cancer treatments.
- Overcoming delivery and specificity challenges is crucial for realizing the full potential of RNAi in oncology.
Related Concept Videos
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:15Experimental RNAi
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...